TY - JOUR
T1 - A modifier screen identifies DNAJB6 as a cardiomyopathy susceptibility gene
AU - Ding, Yonghe
AU - Long, Pamela A.
AU - Martijn Bos, J.
AU - Shih, Yu Huan
AU - Ma, Xiao
AU - Sundsbak, Rhianna S.
AU - Chen, Jianhua
AU - Jiang, Yiwen
AU - Zhao, Liqun
AU - Hu, Xinyang
AU - Wang, Jianan
AU - Shi, Yongyong
AU - Ackerman, Michael J.
AU - Lin, Xueying
AU - Ekker, Stephen C.
AU - Redfield, Margaret M.
AU - Olson, Timothy M.
AU - Xu, Xiaolei
N1 - Publisher Copyright:
© 2016 American Society for Clinical Investigation. All rights reserved.
PY - 2016/9/8
Y1 - 2016/9/8
N2 - Mutagenesis screening is a powerful forward genetic approach that has been successfully applied in lower-model organisms to discover genetic factors for biological processes. This phenotype-based approach has yet to be established in vertebrates for probing major human diseases, largely because of the complexity of colony management. Herein, we report a rapid strategy for identifying genetic modifiers of cardiomyopathy (CM). Based on the application of doxorubicin stress to zebrafish insertional cardiac (ZIC) mutants, we identified 4 candidate CM-modifying genes, of which 3 have been linked previously to CM. The long isoform of DnaJ (Hsp40) homolog, subfamily B, member 6b (dnajb6b(L)) was identified as a CM susceptibility gene, supported by identification of rare variants in its human ortholog DNAJB6 from CM patients. Mechanistic studies indicated that the deleterious, loss-of-function modifying effects of dnajb6b(L) can be ameliorated by inhibition of ER stress. In contrast, overexpression of dnajb6(L) exerts cardioprotective effects on both fish and mouse CM models. Together, our findings establish a mutagenesis screening strategy that is scalable for systematic identification of genetic modifiers of CM, feasible to suggest therapeutic targets, and expandable to other major human diseases.
AB - Mutagenesis screening is a powerful forward genetic approach that has been successfully applied in lower-model organisms to discover genetic factors for biological processes. This phenotype-based approach has yet to be established in vertebrates for probing major human diseases, largely because of the complexity of colony management. Herein, we report a rapid strategy for identifying genetic modifiers of cardiomyopathy (CM). Based on the application of doxorubicin stress to zebrafish insertional cardiac (ZIC) mutants, we identified 4 candidate CM-modifying genes, of which 3 have been linked previously to CM. The long isoform of DnaJ (Hsp40) homolog, subfamily B, member 6b (dnajb6b(L)) was identified as a CM susceptibility gene, supported by identification of rare variants in its human ortholog DNAJB6 from CM patients. Mechanistic studies indicated that the deleterious, loss-of-function modifying effects of dnajb6b(L) can be ameliorated by inhibition of ER stress. In contrast, overexpression of dnajb6(L) exerts cardioprotective effects on both fish and mouse CM models. Together, our findings establish a mutagenesis screening strategy that is scalable for systematic identification of genetic modifiers of CM, feasible to suggest therapeutic targets, and expandable to other major human diseases.
UR - http://www.scopus.com/inward/record.url?scp=85030764348&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030764348&partnerID=8YFLogxK
U2 - 10.1172/jci.insight.88797
DO - 10.1172/jci.insight.88797
M3 - Article
C2 - 27642634
AN - SCOPUS:85030764348
SN - 0021-9738
VL - 1
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 14
M1 - e88797
ER -